10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

BEAM News
Member News
Events

Latest news of BEAM Alliance

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

02 April 2020 - BEAM Alliance

Request for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardship

To support the Antimicrobial Stewardship and Awareness (ASA) Unit in the Global Coordination and Partnership on Antimicrobial Resistance (GCP) department…

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

page 1/4

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

21 September 2020 - Alaxia

Alaxia breaks new ground with lead compound ALX‑009 as virucidal agent

ALX-009 targets antibiotic-multi-resistant Gram negative bacteria (‘super bugs’) that are currently untreatable. It combines two endogenous substances: the hypothiocyanite ion…

10 September 2020 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

01 September 2020 - Aptorum Group Ltd

Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel first-in-class small molecule developed in oral form…

01 September 2020 - Da Volterra

Da Volterra Announces Positive Results from a Phase 1 Clinical Trial Evaluating DAV132 in Healthy Volunteers Receiving ß-lactam Antibiotics

DAV132 is a novel, patented colon-targeted adsorbent developed to protect the intestinal microbiota from the damaging effects of antibiotics. Co-administered…

01 September 2020 - BioVersys AG

BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development

As the world struggles with the challenges brought on by the Covid-19 pandemic, the threat of the next pandemic is…

31 August 2020 - MaaT Pharma

MaaT Pharma Announces Positive Data for its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT

MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes…

page 1/22

Events

26 October 2020

BIO-Europe® 2020 Digital – 26th Annual International Partnering Conference

The 26th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe, though in 2020 by necessity we…

24 September 2020

REVIVE Webinar: Moving from preclinical to clinical-stage: Challenges and opportunities

This webinar was developed in collaboration with CARB-X, JPIAMR, REPAIR Impact Fund, Wellcome Trust, ASM and ESCMID. It is part…

21 September 2020

BioPharm America™ 2020 Digital —13th Annual International Partnering Conference

For this year’s digital event, BioPharm America will focus on Innovation and Investing, with the added collaboration of a number…

25 August 2020

ChinaBio ® Partnering Forum 2020 Digital

ChinaBio® Partnering Forum is the largest and most productive China-focused life science partnering event. To be held as a digital…

24 August 2020

4th AMR Conference Novel Antimicrobial & AMR Diagnostics – Delivered Digitally

In view of the continuing uncertain situation and travel restrictions due to the COVID-19 pandemic, we have decided to implement…

13 July 2020

Curious2020 – Future Insight Virtual Event

This event will feature three key global initiatives to support further advancement in science & technology, solving the challenges of…

09 July 2020

REVIVE Webinar: The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study

In this webinar, Anand Anandkumar and Kamini Walia will discuss: - Why is India one of the hotbeds of the…

09 July 2020

Webinar: Antimicrobial Resistance (AMR): Phenotypic vs. Target-Based Screening

The webinar intends to motivate a revision of the way we feed the research funnel with new ideas, new biology…

09 July 2020

Global Launch – Virtual Event from Berlin: NEW INITIATIVE TAKES ON THE ANTIBIOTIC INNOVATION CHALLENGE

The world is losing its most powerful tool in healthcare: antibiotics. We need to take action now. Organized by IFPMA,…

page 1/7